History
  • No items yet
midpage
333 F. Supp. 3d 1097
D. Colo.
2018
Read the full case

Background

  • Plaintiffs XY, LLC, Beckman Coulter, Inc., and Inguran, LLC sued Trans Ova for patent infringement and other claims; Count XII accused infringement of U.S. Patent No. RE46,559 (the 559 Patent).
  • The 559 Patent claims a method for operating a flow cytometer using at least two detectors, converting detector signals into n‑dimensional data, applying multi‑dimensional mathematical transformations (e.g., rotation, scaling, zooming), classifying particles in real time, and sorting them.
  • The asserted novelty centers on the mathematical processing (compensation algorithms) applied to multi‑dimensional data to improve population separation; hardware (flow cytometer, detectors, fluorescence) reflects well‑known prior art.
  • Trans Ova moved under Rule 12(c) to invalidate the 559 Patent under 35 U.S.C. § 101 (Alice step analysis); XY sought leave to file a fifth amended complaint to add claims on two related patents (367 and 541); Trans Ova sought leave to add an inequitable‑conduct counterclaim concerning the 559 Patent.
  • The court found Claim 1 directed to an abstract idea (mathematical transformation of data) and that the claims add nothing significantly more than the ineligible concept, granted Trans Ova’s § 101 motion, dismissed XY’s Count XII with prejudice, denied XY’s motion to amend as futile, and denied Trans Ova’s amendment as moot.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Whether the 559 Patent claims patent‑eligible subject matter under § 101 (Alice) Patent claims an inventive application of multi‑detector flow cytometry processing; factual disputes (routine/conventional) preclude disposition Claims are directed to an abstract mathematical manipulation of multi‑dimensional data and add nothing inventive beyond conventional flow cytometry Patent is directed to an abstract idea and lacks an inventive concept; § 101 invalidity; Count XII dismissed with prejudice
Whether leave to amend to add infringement claims for the 367 and 541 Patents should be granted Proposed patents assert related inventions derived from same specification and may survive § 101 inquiry; factual issues exist 367 and 541 derive from same disclosure and their asserted novelty is the same mathematical processing; amendment is futile Denied as futile because 367 and 541 would fail the same Alice analysis as the 559 Patent
Whether adding an inequitable‑conduct counterclaim regarding the 559 Patent should be allowed N/A (Trans Ova sought to add it) N/A Denied as moot given court’s holding that the 559 Patent is invalid under § 101
Whether judicial resolution on § 101 was appropriate at the pleading stage XY argued factual disputes (e.g., whether elements are well‑understood/routine) preclude resolution Trans Ova argued claim plain on its face is abstract and lacks inventive concept, permitting disposition on pleadings Court concluded § 101 resolution appropriate here and resolved it at the Rule 12(c) stage

Key Cases Cited

  • Parker v. Flook, 437 U.S. 584 (1978) (mathematical algorithm alone not patentable; post‑solution activity cannot make it so)
  • Diamond v. Diehr, 450 U.S. 175 (1981) (combination of steps applying an equation may be patentable if it transforms process into inventive application)
  • Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012) (claims that add only conventional steps to a natural law are patent ineligible)
  • Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014) (two‑step test for patent eligibility: directed to ineligible concept, then inventive concept inquiry)
  • Elec. Power Grp., LLC v. Alstom S.A., 830 F.3d 1350 (Fed. Cir. 2016) (collecting, analyzing, and displaying information constitutes an abstract idea)
  • Cleveland Clinic Found. v. True Health Diagnostics LLC, 859 F.3d 1352 (Fed. Cir. 2017) (claim directed to a natural law or correlation is patent ineligible when testing methods are conventional)
  • Berkheimer v. HP Inc., 881 F.3d 1360 (Fed. Cir. 2018) (whether claim elements are well‑understood, routine, and conventional can be a factual question preventing disposition on pleadings)
Read the full case

Case Details

Case Name: Xy, LLC v. Trans Ova Genetics, LC
Court Name: District Court, D. Colorado
Date Published: Aug 9, 2018
Citations: 333 F. Supp. 3d 1097; Civil Action No. 17-cv-0944-WJM-NYW
Docket Number: Civil Action No. 17-cv-0944-WJM-NYW
Court Abbreviation: D. Colo.
Log In
    Xy, LLC v. Trans Ova Genetics, LC, 333 F. Supp. 3d 1097